Monetta Financial Services Inc. Takes Position in Illumina, Inc. $ILMN

Monetta Financial Services Inc. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,500 shares of the life sciences company’s stock, valued at approximately $807,000.

A number of other hedge funds have also recently added to or reduced their stakes in ILMN. Assetmark Inc. raised its stake in shares of Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after buying an additional 96 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Illumina by 8.9% in the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after buying an additional 111 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares in the last quarter. Archer Investment Corp grew its holdings in Illumina by 12.9% during the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after acquiring an additional 123 shares during the period. Finally, Callan Family Office LLC raised its position in Illumina by 4.4% in the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after acquiring an additional 124 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 2.4%

Shares of NASDAQ ILMN opened at $120.54 on Tuesday. The firm’s 50-day moving average is $135.52 and its two-hundred day moving average is $117.54. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The company has a market capitalization of $18.43 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 2.25 and a beta of 1.45. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the previous year, the company earned $0.95 EPS. Illumina’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on ILMN shares. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Guggenheim raised their price objective on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Canaccord Genuity Group upped their target price on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $127.94.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.17% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.